The following is a summary of major deals in the life science
space that closed or were announced as closed in January 2017.
Vancouver-based Quark Venture Inc., through its Global Health
Sciences Venture Fund, continued to be an active investor, with
investments made both in Canada and the United States in the month
of January 2017.
MERGERS & ACQUISITIONS
Date: Closed January 3, 2017
Type: Amalgamation
Companies: Avagenesis Corp (TSXV: VVA) and
Avapecia Life Sciences Corp. (CSE: VVS)
Deal size: Approx. CDN $12.13 million
Description: On January 3, 2017, Avapecia Life
Sciences Corp. ("Avapecia") and
Avagenesis Corp. ("Avagenesis")
announced the completion of the transactions contemplated in their
amalgamation agreement dated November 10, 2016. The amalgamated
company, Liberty Biopharma Inc.
("Liberty"), will continue the business
of both Avagenesis and Avapecia. Its common shares were listed on
the TSX Venture Exchange under the symbol "LTY" on
January